Evidence-based·Updated November 14, 2026·How we grade evidence

Apixaban

MedicationAnticoagulant (prescription)

In large trials, apixaban prevented more strokes than warfarin in atrial fibrillation with less major bleeding, prevented more strokes than aspirin in people who could not take warfarin, treated leg and lung clots with less bleeding than standard therapy, and, in people who had already finished 6 to 12 months of treatment, prevented more repeat clots than a placebo. Its main risk is bleeding. St. John's wort is the most important supplement interaction; vitamin E, fish oil and chia need a conversation with your prescriber.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults with atrial fibrillation not caused by a valve problem, people who have had a leg or lung blood clot, and people recovering from hip or knee replacement, when a prescriber recommends anticoagulation

Common dosing range

Set by your prescriber. The label dose for atrial fibrillation is 5 mg twice daily, or 2.5 mg twice daily for people with at least two of: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher

When to expect effects

Peak levels 3 to 4 hours after a dose; the effect wears off over about 24 hours, which is why missed doses matter

Watch out for

Boxed warnings: stopping early raises the risk of stroke and clots, and spinal or epidural bleeding can occur with spinal procedures. Serious bleeding can happen. Avoid St. John's wort, and talk to your prescriber before taking aspirin, NSAIDs, high-dose vitamin E or high-dose omega-3

What is it

Apixaban is a prescription blood thinner (anticoagulant) taken by mouth, sold under the brand name Eliquis. It belongs to the direct oral anticoagulants, sometimes called DOACs. The FDA label approves it to lower the risk of stroke and blood clots in adults with atrial fibrillation not caused by a heart valve problem, to prevent clots after hip or knee replacement, to treat clots in the legs (deep vein thrombosis) or lungs (pulmonary embolism) and lower the chance they come back, and, in children from birth onward, to treat clots and lower the chance they come back after at least 5 days of initial blood-thinner treatment. It is given at fixed doses; the label notes that standard clotting tests such as the INR are not useful for monitoring its effect.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have atrial fibrillation with stroke risk factors and you and your prescriber chose apixaban
You had a blood clot in a leg vein or the lungs and your prescriber recommends treatment or extended prevention
You are recovering from hip or knee replacement and your surgeon prescribes it for a set number of days
You can take a dose twice a day reliably and tell every clinician, including your dentist, that you take it

Probably skip if…

You have active bleeding (the label lists this as a contraindication)
You have a mechanical or other prosthetic heart valve, where the label does not recommend it
You have triple-positive antiphospholipid syndrome, where the label does not recommend direct oral anticoagulants
You plan to keep taking St. John's wort, or to add blood-thinning supplements without telling your prescriber

Evidence at a glance

stroke prevention in atrial fibrillation (versus warfarin)

Good Evidence
Effect
Moderate; 21% fewer strokes or emboli and 31% less major bleeding than warfarin
Best fit
Adults with atrial fibrillation not caused by a valve problem and at least one added stroke risk factor
Time
Protection while taking it; the anticoagulant effect wears off within about a day of the last dose

stroke prevention in atrial fibrillation when warfarin is unsuitable (versus aspirin)

Good Evidence
Effect
Large; about 55% fewer strokes or emboli than aspirin, with similar major bleeding
Best fit
Adults with atrial fibrillation and stroke risk for whom warfarin is unsuitable
Time
Protection while taking it

treatment of leg and lung blood clots

Good Evidence
Effect
Similar clot prevention to standard therapy, with about 69% less major bleeding
Best fit
Adults with a new leg vein clot or pulmonary embolism
Time
Treatment ran 6 months in the trial; benefit lasts only while it is taken

preventing repeat clots after initial treatment

Good Evidence
Effect
Large; about 7 fewer repeat clots per 100 people over a year
Best fit
People who finished 6 to 12 months of treatment for a clot and are at continuing risk
Time
Throughout the 12 months studied; benefit lasts only while it is taken

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

stroke prevention in atrial fibrillation (versus warfarin)

Disease adjunct
Good Evidence

In the ARISTOTLE trial, 18,201 people with atrial fibrillation and at least one other stroke risk factor were randomly assigned to apixaban 5 mg twice daily or warfarin and followed for a median of 1.8 years. Stroke or systemic embolism occurred at 1.27% per year with apixaban versus 1.60% with warfarin (hazard ratio 0.79). Major bleeding was lower (2.13% versus 3.09% per year), hemorrhagic stroke was about halved (0.24% versus 0.47%), and death from any cause was slightly lower (3.52% versus 3.94%). Ischemic stroke alone did not differ significantly. This is one large, double-blind, industry-funded trial.

Effect size
Moderate; 21% fewer strokes or emboli and 31% less major bleeding than warfarin
Time to effect
Protection while taking it; the anticoagulant effect wears off within about a day of the last dose
Best fit
Adults with atrial fibrillation not caused by a valve problem and at least one added stroke risk factor
Less likely
People with prosthetic heart valves or significant valve disease, who were not the trial population

Bottom line: Apixaban prevented slightly more strokes than warfarin with less bleeding.

stroke prevention in atrial fibrillation when warfarin is unsuitable (versus aspirin)

Disease adjunct
Good Evidence

The AVERROES trial randomly assigned 5,599 people with atrial fibrillation who could not or would not take warfarin to apixaban 5 mg twice daily or aspirin 81 to 324 mg daily. It was stopped early for clear benefit after a mean of 1.1 years: stroke or systemic embolism occurred at 1.6% per year with apixaban versus 3.7% with aspirin (hazard ratio 0.45). Major bleeding was similar (1.4% versus 1.2% per year), and the difference in deaths (3.5% versus 4.4% per year) was not statistically significant.

Effect size
Large; about 55% fewer strokes or emboli than aspirin, with similar major bleeding
Time to effect
Protection while taking it
Best fit
Adults with atrial fibrillation and stroke risk for whom warfarin is unsuitable
Less likely
People at very low stroke risk

Bottom line: Apixaban prevented more than half of strokes compared with aspirin, without more major bleeding.

treatment of leg and lung blood clots

Disease adjunct
Good Evidence

In the AMPLIFY trial, 5,395 people with an acute deep vein thrombosis or pulmonary embolism received apixaban (10 mg twice daily for 7 days, then 5 mg twice daily for 6 months) or standard enoxaparin injections followed by warfarin. Recurrent clots or clot-related death occurred in 2.3% versus 2.7%, meeting the test for noninferiority. Major bleeding was lower with apixaban (0.6% versus 1.8%), as was major plus clinically relevant bleeding (4.3% versus 9.7%).

Effect size
Similar clot prevention to standard therapy, with about 69% less major bleeding
Time to effect
Treatment ran 6 months in the trial; benefit lasts only while it is taken
Best fit
Adults with a new leg vein clot or pulmonary embolism
Less likely
People needing more than the 6 months of treatment tested here (see the extended-treatment trial)

Bottom line: Apixaban treats leg and lung clots as well as standard therapy with less bleeding.

preventing repeat clots after initial treatment

Disease adjunct
Good Evidence

AMPLIFY-EXT enrolled 2,486 people who had completed 6 to 12 months of anticoagulation for a clot and whose doctors were unsure whether to continue. Over 12 months, repeat clots or clot-related death occurred in 8.8% on placebo versus 1.7% on apixaban 2.5 mg and 1.7% on 5 mg twice daily. Major bleeding was 0.5% on placebo, 0.2% on 2.5 mg and 0.1% on 5 mg; clinically relevant nonmajor bleeding was somewhat higher on apixaban (3.0% and 4.2% versus 2.3%).

Effect size
Large; about 7 fewer repeat clots per 100 people over a year
Time to effect
Throughout the 12 months studied; benefit lasts only while it is taken
Best fit
People who finished 6 to 12 months of treatment for a clot and are at continuing risk
Less likely
People whose doctors judge that a limited course of anticoagulation is enough

Bottom line: Continuing apixaban sharply cut repeat clots without more major bleeding.

How it works

Apixaban directly blocks factor Xa, a key clotting protein. Blocking it reduces the production of thrombin, so clots form less easily. It does not act on platelets directly. Its effect lasts at least 24 hours after the last dose, about two half-lives of roughly 12 hours each. Apixaban is cleared partly by the liver enzyme CYP3A4 and the transporter P-glycoprotein. Products that strongly speed up both, such as St. John's wort, lower apixaban levels and can leave you less protected against stroke and clots, while drugs that strongly block both raise levels and bleeding risk. Separately, anything else that affects bleeding (aspirin, NSAIDs, some antidepressants, and possibly high-dose vitamin E or omega-3) can add to apixaban's bleeding risk. Vitamin K does not reverse apixaban, so there is no vitamin K diet rule like the one for warfarin.

How to take it

1. Typical dose
Your prescriber sets the dose. The label recommends 5 mg twice daily for atrial fibrillation (2.5 mg twice daily with at least two of: age 80 or older, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher); 10 mg twice daily for 7 days, then 5 mg twice daily, to treat a leg or lung clot; 2.5 mg twice daily to lower the chance of a repeat clot after at least 6 months of treatment; and 2.5 mg twice daily after hip (35 days) or knee (12 days) replacement, starting 12 to 24 hours after surgery.
2. Higher studied dose
The highest labeled dose is 10 mg twice daily for the first 7 days of clot treatment. Prescribers halve the dose, or avoid apixaban, with certain strong interacting drugs.
3. Timing
Twice a day, about 12 hours apart. If you miss a dose, the label says to take it as soon as possible on the same day and then resume twice-daily dosing; do not double a dose.
4. With food
With or without food; food does not change how much is absorbed. If you cannot swallow tablets, the label allows crushing them into water, apple juice or applesauce and taking it promptly.
5. Split dosing
Taken as two doses a day.
6. How long to try
Set by the condition and your prescriber: 12 or 35 days after knee or hip replacement, a treatment course after a clot (with a lower dose after at least 6 months if it is continued), and often long-term for atrial fibrillation. Do not stop without talking to your prescriber, because stopping early raises the risk of stroke and clots.

What to track

Signs of bleeding: unusual bleeding from the gums, frequent nosebleeds, heavier periods, red, pink or brown urine, red or black tar-like stools, coughing up or vomiting blood
Any fall or injury, especially if you hit your head (call your healthcare provider right away)
Numbness or weakness in the legs or bowel or bladder problems after a spinal or epidural procedure (urgent)
Every new medicine or supplement, which you should clear with your pharmacist
Upcoming surgery, medical or dental procedures: tell every provider and dentist you take apixaban so they can talk with your prescriber first

Bottom line: Your prescriber sets the dose; take it twice a day without gaps and check supplements first.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Bleeding, the most common side effectBleeding gums, nosebleeds and bruisingBlood in the urine or from the rectum, and heavier periodsSmall collections of blood under the skin (hematoma)

Serious risks

Who should avoid it

Pregnancy & breastfeeding

The Eliquis label lists use in pregnancy as not recommended. It says the limited data in pregnancy are not enough to judge the risk of birth defects or miscarriage, that treatment may increase bleeding during pregnancy and delivery and in the fetus and newborn, and that a shorter-acting anticoagulant may be considered as delivery approaches because of epidural risks. People who could become pregnant should discuss pregnancy planning with their prescriber. Breastfeeding: there are no data on apixaban in human milk; it accumulated in rat milk, and the label says breastfeeding is not recommended during treatment.

Interactions

St. John's wortHigh

St. John's wort strongly speeds up both CYP3A4 and P-glycoprotein, which clear apixaban. The Eliquis label names it among products to avoid with apixaban because it lowers apixaban levels and raises the risk of stroke and clots. If you take it, talk to your doctor or pharmacist promptly rather than stopping anything on your own.

Vitamin E (high-dose supplements)High

Vitamin E has anticoagulant properties. In 566 people with atrial fibrillation on warfarin (mean age 73.6), those who bled had higher blood vitamin E levels and levels predicted bleeding, an association rather than proof; the authors said it is unknown whether this holds for newer anticoagulants such as apixaban. Talk to your doctor or pharmacist before taking a high-dose vitamin E supplement.

Ketoconazole, itraconazole, ritonavir and other combined P-gp and strong CYP3A4 inhibitorsHigh

These drugs raise apixaban levels and bleeding risk. The label says to halve the apixaban dose for people on 5 mg or 10 mg twice daily, and to avoid the combination for people already on 2.5 mg twice daily. Clarithromycin is an exception that the label says needs no dose change.

Rifampin, carbamazepine, phenytoin and other combined P-gp and strong CYP3A4 inducersHigh

These drugs lower apixaban levels and raise the risk of stroke and clots, and the label says to avoid using them together.

Aspirin, NSAIDs (ibuprofen, naproxen), other blood thinners, SSRIs and SNRIsHigh

The label lists these among drugs that increase bleeding risk with apixaban. In ARISTOTLE, adding aspirin raised the bleeding rate on apixaban from 1.8% to 3.4% per year. Ask your pharmacist before using any over-the-counter pain reliever.

Fish oil (omega-3 supplements)Moderate

Omega-3 fats have raised concern about bleeding. A 2024 meta-analysis of 11 randomized trials in 120,643 people found no overall increase in bleeding with omega-3 (rate ratio 1.09, not significant), but high-dose purified EPA raised the relative risk of bleeding by about 50% with a small absolute increase. These trials did not focus on people taking apixaban. Tell the clinician who manages your apixaban about any fish oil, especially high-dose or prescription omega-3.

Chia seedsLow

Chia is a food rich in fiber and plant omega-3 (ALA). In a 12-week trial in 20 adults with type 2 diabetes eating about 37 g a day, chia lowered von Willebrand factor, a clotting protein, by 21% without changing hemostatic safety tests. There are no studies in people taking apixaban, so the concern is theoretical; mention a daily chia habit to your doctor or pharmacist.

Documented interactions

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Eliquis or a generic apixaban product dispensed by a licensed pharmacy on your own prescription
The tablet strength (2.5 mg or 5 mg) and whether you are in a starter pack phase of clot treatment
A Medication Guide with each fill
Medication Guide advice to tell all your healthcare providers and dentists that you take apixaban before any procedure

Be skeptical of…

Supplements marketed as "natural blood thinners" or "circulation support" presented as safe to combine with apixaban, or as a replacement for it
Mood or sleep blends that contain St. John's wort without a clear warning
High-dose vitamin E or high-dose omega-3 products promoted as harmless with anticoagulants
Advice to skip doses before procedures on your own, without your prescriber's plan

Frequently asked questions

Do I need to limit leafy greens or vitamin K on Eliquis?⌄

No vitamin K diet rule applies to apixaban the way it does to warfarin. The Eliquis label notes that vitamin K is not expected to affect apixaban's anticoagulant activity. A normal, balanced diet is fine; ask your pharmacist if you are switching from warfarin and are unsure.

Can I take fish oil with Eliquis?⌄

Tell your prescriber first. A 2024 meta-analysis found no overall increase in bleeding with omega-3 supplements, but high-dose purified EPA raised the relative bleeding risk by about 50%. Those trials were not specifically in people taking apixaban, so your prescriber can weigh your own bleeding risk.

Can I take St. John's wort with Eliquis?⌄

The Eliquis label says to avoid it. St. John's wort speeds up the clearance of apixaban and can lower its levels, raising the risk of stroke and clots. If you already take it, talk to your doctor or pharmacist promptly.

Is vitamin E safe with Eliquis?⌄

This page rates high-dose vitamin E as a high-severity interaction. Vitamin E has anticoagulant properties, and in people taking warfarin higher vitamin E levels were linked to more bleeding. It has not been studied with apixaban, so ask your doctor or pharmacist before taking a supplement.

What should I do if I miss a dose?⌄

The label says to take it as soon as you remember on the same day, then go back to your usual twice-daily schedule. Do not take two doses at once to make up for a missed one.

Can I take ibuprofen or aspirin with Eliquis?⌄

The label lists aspirin and NSAIDs such as ibuprofen and naproxen among drugs that increase bleeding risk with apixaban. Ask your doctor or pharmacist which pain reliever is appropriate for you.

References by claim

stroke prevention in atrial fibrillation (versus warfarin)

Granger et al., 2011 · PubMed (2011) link

stroke prevention in atrial fibrillation when warfarin is unsuitable (versus aspirin)

Connolly et al., 2011 · PubMed (2011) link

treatment of leg and lung blood clots

Agnelli et al., 2013 · PubMed (2013) link

preventing repeat clots after initial treatment

Agnelli et al., 2013 · PubMed (2013) link

Safety

Eliquis (apixaban) prescribing information · DailyMed (FDA label) link

Interaction: Vitamin E (high-dose supplements)

Pastori et al., 2013 · PMC (2013) link

Interaction: Fish oil (omega-3 supplements)

Javaid et al., 2024 · PMC (2024) link

Interaction: Chia seeds

Vuksan et al., 2007 · PubMed (2007) link

Track Apixaban with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 14, 2026·Evidence current as of Nov 14, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.